B-LIVER
THE BRUSSELS LIVER RESEARCH TO VALORISATION CONSORTIUM
EXPERTISE
The B-LIVER Consortium consolidates 30+ years of expertise in liver cell biology, pathology and toxicology. In addition to maintaining a robust network of scientific connections within academic institutions and regulatory bodies, B-LIVER team members are also actively engaged in multiple valorisation trajectories covering their various research projects through partnerships with key industrial partners. Ongoing activities are grouped into 3 strategic clusters: • Innovative Therapeutics (fatty liver disease, fibrosis, inflammatory diseases, inherited metabolic disorders). • Next Generation Risk Assessment (Drug-Induced Liver Injury, Hazard-to-Risk Translation, conventional and advanced in vitro liver models). • Stakeholder Engagement (dissemination, education, partnership building).
CONTACT In Vitro Toxicology & DermatoCosmetology Vrije Universiteit Brussel / Building G Laarbeeklaan 103 1090 Brussel Tamara Vanhaecke Coordinator B-Liver / Head IVTD
Tamara.Vanhaecke@vub.be Leo Van Grunsven Head LIVR
Leo.van.Grunsven@vub.be Freddy Van Goethem Valorisation Manager B-LIVER
Freddy.Van.Goethem@vub.be
human skin stem cell-derived hepatic cells
GROUP OF EXCELLENCE IN APPLIED RESEARCH - GEAR
The Brussels Liver Research to Valorisation Consortium unites the liver cell biology, pathology and toxicology expertise of Vrije Universiteit Brussels’ IVTD and LIVR research groups. B-Liver’s mission is primarily grounded in established models and technology, but also extends into higher-risk emerging innovations towards liver modelling, toxicity prediction and therapeutic strategies in liver disease. An key goal is developing in vitro liver models, adhering to the 3Rs principle (Reduction, Replacement, Refinement) to minimize animal use in research and testing.